These agreements include new partnerships and extensions to old agreements with CeNes, Gemin X Biotechnologies, Genzyme Corp, GlaxoSmithKline R&D, and Schering-Plough Research Institute.
The agreements were all finalized in the fourth quarter of 2005. Terms of the agreements were not disclosed.
According to Tripos the partnerships encompass a range of research activities including medicinal chemistry programs, the development of new LeadQuest compounds, follow-up libraries based on hits from LeadQuest, provision of synthetic protocols, fragment-based screening and LeadHopping projects.
“Their (the companies) decision to select Tripos as their drug discovery partner underscores the quality of our work, the innovation we bring to our partners and our solid reputation for success in this field,” said Dr John McAlister, president and CEO of Tripos.